# A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

> **NCT07169708** · — · NOT_YET_RECRUITING · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07169708
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169708, "A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07169708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*